Search

Your search keyword '"Kaycee M Sink"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Kaycee M Sink" Remove constraint Author: "Kaycee M Sink"
170 results on '"Kaycee M Sink"'

Search Results

1. Alzheimer's disease risk assessment using large-scale machine learning methods.

2. Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations

3. Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment

4. Changes in metabolic risk factors over 10 years and their associations with late‐life cognitive performance: The Multi‐Ethnic Study of Atherosclerosis

5. Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial

6. Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial

7. Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial

8. API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

9. Community-Based Activity and Sedentary Patterns Are Associated With Cognitive Performance in Mobility-Limited Older Adults

10. Robust demographically-adjusted normative data for the Montreal Cognitive Assessment (MoCA): Results from the systolic blood pressure intervention trial

11. The relationship between depressive symptoms and subtypes of mild cognitive impairment in post‐menopausal women: Results from the Women's Health Initiative Memory Study

12. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials

13. Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers

14. Corrigendum: Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images

15. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial

16. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

17. Prognostic Awareness, Disease and Palliative Understanding Among Caregivers of Patients With Dementia

18. Strategies for activity maintenance in patient and family care and clinical trial adherence of GNA social plan in context of COVID‐19 health emergency

19. Mild cognitive impairment and transitions in cognitive status in the Systolic Blood Pressure Intervention Trial (SPRINT)

20. Psychological status in the participants of the API ADAD Colombia trial assisted by a comprehensive mental health program during COVID 19 pandemic

21. Effect of Intensive Blood Pressure Control on Subtypes of Mild Cognitive Impairment and Risk of Progression from SPRINT study

22. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure

23. The Association between the Montreal Cognitive Assessment and Functional Activity Questionnaire in the Systolic Blood Pressure Intervention Trial (SPRINT)

24. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control

25. Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer’s disease: Baseline findings from the API ADAD trial

26. Intraindividual Variability in Domain-Specific Cognition and Risk of Mild Cognitive Impairment and Dementia

27. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

28. Computer simulations for assessing cognitively intensive instrumental activities of daily living in older adults

29. Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus

30. Negative Affect Is Associated With Higher Risk of Incident Cognitive Impairment in Nondepressed Postmenopausal Women

31. Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features

32. Effects of Intensive BP Control in CKD

33. The Feasibility of Walnut and Extra Virgin Olive Oil Supplementation in Older Adults

34. Integrating Frailty Research into the Medical Specialties-Report from a U13 Conference

35. Dynapenia and Metabolic Health in Obese and Nonobese Adults Aged 70 Years and Older: The LIFE Study

36. Changes in metabolic risk factors over 10 years and their associations with late-life cognitive performance: The Multi-Ethnic Study of Atherosclerosis

37. Prediction and Classification of Alzheimer’s Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers

38. Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment

39. New Perspective for Non-invasive Brain Stimulation Site Selection in Mild Cognitive Impairment: Based on Meta- and Functional Connectivity Analyses

40. P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE

41. Performing Sparse Regularization and Dimension Reduction Simultaneously in Multimodal Data Fusion

42. Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients

43. The Influence of Cerebrospinal Fluid Abnormalities and APOE 4 on PHF-Tau Protein: Evidence From Voxel Analysis and Graph Theory

44. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial

45. APOE Genotypes Associate With Cognitive Performance but Not Cerebral Structure: Diabetes Heart Study MIND

46. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume

47. COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P)

48. P4‐209: A PUBLIC RESOURCE OF BASELINE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL

49. P3‐019: THE EFFECTS OF DIET INTERVENTION ON METABOLIC HEALTH AND CEREBRAL SPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS: A RANDOMIZED TRIAL

50. O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD)

Catalog

Books, media, physical & digital resources